“One Stop Solution – Gene to Protein to Antibody”
Incorporation
BIG-BIRAC
(~ 5 Million INR)
Indo-French CEFIPRA
(~1 Million)
Recombinant Antibody Platform Developed Range of Products
Two Patents from Development
WiNER Award
(~0.5 Million INR)
Technology Hotspot Award at Select Bio
BIRAC-PACE Grant
(~ 5 Million INR)
ISO 9001: 2015 Quality Management Certification
National Biopharma Mission
(~ 10 Million INR)
DSIR Accredition MoST, GOI
Samriddhi Grant
Established in 2011, Genext Genomics Pvt Ltd is an emerging life science research start up and contract research organization in central india, with focus on providing purpose-based solution for life science customers, a one stop solution for all your protein needs! Founded and managed by a team of scientists with extensive experience in both academia and industry, GNG is working for development of recombinant proteins and monoclonal antibodies against clinically relevant targets through the integration of bioinformatics, recombinant DNA technology, proteomics and immunology using novel high-throughput technologies.
GeNext Genomics has proprietary phage display library for production of high affinity monoclonal antibodies and has been specialized in applying the technologies for wide range of service project.
Cloning the gene, Sub cloning in the expression vector, Upstream- expression and purification at analytical scale; downstream process – scale up
Immunization of antigen, fusion, Production of hybridoma, Single cell cloning, Mab production
Cloning scfv in E.Coli expression vector, Cloning of full IgG in CHO expression system
An Antibody Engineering Service against tumor necrosis factor-alpha (TNF-α), like infliximab, is an attractive therapeutic approach[…]
The serious acute respiratory syndrome covid 2 is the etiological agent of the covid induced disease[…]
In protein research, the term may apply to either the object of study or the laboratory[…]
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.